FDA OKs generic abortion pill, riling the right
The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
What happened
The Food and Drug Administration has approved a second generic version of mifepristone, the drug used in combination with misoprostol to carry out roughly two-thirds of U.S. abortions, drugmaker Evita Solutions announced Thursday. The FDA approved mifepristone in 2000 and the first generic version in 2019.
Who said what
“Approval of a second generic is unlikely to affect access” to mifepristone, The Associated Press said, but the FDA’s quiet approval of Evita’s application “triggered pushback from anti-abortion groups and politicians aligned with the Trump administration.” Students for Life Action called the move “a stain on the Trump presidency and another sign that the deep state at the FDA must go.”
This was the “first significant pushback” President Donald Trump has gotten from his “otherwise loyal base of social conservatives,” The Washington Post said. Less than two weeks ago, anti-abortion activists celebrated a promise from FDA Commissioner Marty Makary and Health and Human Services Secretary Robert F. Kennedy Jr. to review mifepristone’s safety. HHS spokesperson Andrew Nixon said Thursday that “the FDA has very limited discretion in deciding whether to approve a generic drug.”
What next?
“I think the intelligent people in the pro-life movement don’t want to go to war with the administration,” a consultant for anti-abortion groups told the Post. “If you do something that embarrasses Trump and the HSS secretary and the high-profile people, then you wind up with Trump digging in his heels — and you don’t want that.” Evita said it expects its version of mifepristone to become available in January.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Trump vs. BBC: what’s at stake?The Explainer The US president has filed a $10 billion lawsuit over the editing of Panorama documentary, with the broadcaster vowing to defend itself
-
Animal Farm: has Andy Serkis made a pig’s ear of Orwell?Talking Point Animated adaptation of classic dystopian novella is light on political allegory and heavy on lowbrow gags
-
What new cryptocurrency regulations mean for investorsThe Explainer The Treasury and the Financial Conduct Authority aim to make the UK a more attractive and safer place for crypto assets
-
Stopping GLP-1s raises complicated questions for pregnancyThe Explainer Stopping the medication could be risky during pregnancy, but there is more to the story to be uncovered
-
The controversial Free Birth SocietyThe Explainer Influencers are encouraging pregnant women to give birth without midwife care – at potentially tragic cost
-
Vaccine critic quietly named CDC’s No. 2 officialSpeed Read Dr. Ralph Abraham joins another prominent vaccine critic, HHS Secretary Robert F. Kennedy Jr.
-
More adults are dying before the age of 65Under the radar The phenomenon is more pronounced in Black and low-income populations
-
Scientists have developed a broad-spectrum snake bite antivenomUnder the radar It works on some of the most dangerous species
-
More women are using more testosterone despite limited researchThe explainer There is no FDA-approved testosterone product for women
-
The ‘menopause gold rush’Under the Radar Women vulnerable to misinformation and marketing of ‘unregulated’ products
-
How medical imposters are ruining health studiesUnder the Radar Automated bots and ‘lying’ individuals ‘threaten’ patient safety and integrity of research
